Sagimet Biosciences INC 8-K filings

Sagimet Biosciences Inc. announced the FDA has cleared its Investigational New Drug application for a Phase 3 trial of denifanstat in acne.

Sagimet Biosciences announced its second quarter 2026 financial results, highlighting a robust cash position and progress in its denifanstat and TVB-3567 clinical programs for acne treatment.

Sagimet Biosciences reports the resignation of director Tim Walbert and the successful election of four Class III directors at its 2026 Annual Meeting.

Sagimet Biosciences announced first quarter 2026 financial results, highlighting a $175 million equity financing and plans to initiate a Phase 3 acne trial in the second half of 2026.

Sagimet Biosciences Inc. announced the pricing of an underwritten public offering of 29,166,700 shares of its common stock at $6.00 per share, expecting net proceeds of $164.5 million.

Sagimet Biosciences Inc. provided an update on its FASN inhibitor programs, denifanstat and TVB-3567, highlighting clinical trial progress and future development plans for acne and MASH indications.

Sagimet Biosciences provides updates on its lead drug denifanstat for acne and MASH, and its second FASN inhibitor TVB-3567, with key clinical trial timelines and strategic financial planning.

Sagimet Biosciences Inc. reported the retirement of its Chief Medical Officer, Eduardo Martins, M.D., D.Phil., effective April 20, 2026, and announced the appointment of Andreas Grauer, M.D. to the same role.

Sagimet Biosciences announced positive 52-week long-term safety and efficacy data from its license partner Ascletis's Phase 3 clinical trial of denifanstat for moderate to severe acne in China.

Sagimet Biosciences announced positive Phase 1 pharmacokinetic trial results for its denifanstat and resmetirom combination therapy for MASH, alongside the acceptance of its denifanstat NDA for acne in China.

Sagimet Biosciences secured a global, exclusive license from TAPI for innovative resmetirom API forms to develop a fixed-dose combination product for MASH.

Sagimet Biosciences reported its third quarter 2025 financial results, highlighted by progress in its MASH and acne clinical programs, including a new combination trial and a partner's NDA submission plan.

Sagimet Biosciences Inc. updated its investor presentation, highlighting progress in its MASH, acne, and oncology programs, including positive Phase 2b denifanstat data and new combination trials.

Sagimet Biosciences Inc. announced the appointment of KPMG LLP as its new independent registered public accounting firm, replacing Deloitte & Touche LLP, effective immediately.

Sagimet Biosciences Inc. has established a new 'at-the-market' equity offering program to sell up to $75 million in common stock, replacing a prior unused agreement.

Sagimet Biosciences reports strong Q2 2025 progress, highlighted by partner's successful Phase 3 acne trial and new combination therapy plans for MASH.

Sagimet Biosciences Inc. has updated executive severance packages to align with market practices and confirmed the election of two Class II directors and the ratification of its independent auditor at its 2025 Annual Meeting of Stockholders.

Sagimet Biosciences reported that its partner Ascletis's Phase 3 trial of denifanstat for moderate to severe acne met all primary and secondary endpoints in China, while Sagimet initiated a Phase 1 trial for a new FASN inhibitor, TVB-3567, for acne in the U.S.

Sagimet Biosciences announced its first quarter 2025 financial results and provided corporate updates, including plans to initiate a Phase 1 clinical trial for a combination therapy targeting MASH.

Merdad Parsey, M.D., Ph.D., will not seek re-election to Sagimet Biosciences' board of directors at the upcoming 2025 Annual Meeting of Stockholders.

Sagimet Biosciences announces full year 2024 financial results, initiation of Phase 3 MASH program, FDA Breakthrough Therapy designation for denifanstat, and IND clearance for TVB-3567 for acne treatment.

Sagimet Biosciences announces the FDA clearance of its Investigational New Drug (IND) application for TVB-3567, a second fatty acid synthase (FASN) inhibitor, paving the way for a Phase 1 clinical trial in acne treatment.

Sagimet Biosciences highlights the progress of its lead molecule, denifanstat, across multiple indications including MASH, acne, and cancer, along with its financial status and strategic collaborations.

Sagimet Biosciences has released an investor presentation highlighting the progress of its clinical programs, particularly denifanstat, and its financial status.

Sagimet Biosciences reported its third quarter 2024 financial results, highlighted by the FDA's Breakthrough Therapy designation for denifanstat and progress towards a Phase 3 program.

Sagimet Biosciences has entered into an agreement to potentially sell up to $75 million of its Series A common stock through an at-the-market offering.

Sagimet Biosciences announced positive results from its Phase 2b FASCINATE-2 trial for denifanstat in MASH and is preparing to initiate a Phase 3 program in the second half of 2024.

Sagimet Biosciences has increased its board size from seven to nine members, appointing Jennifer Jarrett and Dr. Anne Phillips as independent directors effective August 1, 2024.

Sagimet Biosciences has released an updated investor presentation highlighting positive Phase 2b results for denifanstat in MASH and progress in acne and cancer programs.

Sagimet Biosciences reported statistically significant positive results from its FASCINATE-2 Phase 2b clinical trial of denifanstat for treating metabolic dysfunction-associated steatohepatitis (MASH), showing improvements in liver fibrosis and other key endpoints.